FDA Fast-Tracks Pancreatic Cancer Drug That Could Double Survival
Updated
Updated · WJXT News4JAX · May 12
FDA Fast-Tracks Pancreatic Cancer Drug That Could Double Survival
5 articles · Updated · WJXT News4JAX · May 12
Fast-track status from the FDA has put an experimental pancreatic cancer drug on a quicker approval path after testing suggested it could double survival in patients with advanced disease.
Advanced pancreatic cancer is the focus of the treatment, with the reported survival gain driving descriptions of the trial as a watershed moment in cancer care.
Dr. Bijoy Telivala, an oncologist with Cancer Specialists of North Florida, said the drug's results point to a potentially major shift in how one of the deadliest cancers is treated.
New drugs treat advanced cancer, but a test finds it early. Is the real breakthrough in treatment or detection?
A new cancer drug is available before full approval. Who is eligible, and how can they access it today?
Two rival drugs are poised to revolutionize pancreatic cancer treatment. Which one offers patients the most hope?
Daraxonrasib Offers Hope: FDA Accelerates Review as New Drug Doubles Survival in Advanced Pancreatic Cancer
Overview
The FDA is moving quickly to review daraxonrasib, a new drug that brings hope to patients with pancreatic cancer—a disease that is very hard to treat and often deadly within months. Pancreatic cancer has one of the worst outcomes in oncology, with over 50,000 deaths each year in the U.S. and a five-year survival rate of just 3% for advanced cases. Because of these grim statistics, there is an urgent need for better treatments. Daraxonrasib’s promising results in trials have led the FDA to fast-track its review, aiming to offer new options for those facing this challenging disease.